September 17, 2010 11:21 AM
- Text
First Over-The-Counter Diet Pill Gets OK
(CBS/AP)
Dieters got a new tool Wednesday to help them take off the extra pounds — the first government-approved nonprescription diet pill.
The Food and Drug Administration said the fat-blocking weight-loss pill orlistat, which has been available by prescription, can be sold in a reduced-strength version over the counter.
The new version will be sold as "alli" by GlaxoSmithKline PLC. Xenical, the prescription version, is made by Roche Holding AG.
GlaxoSmithKline chose the name "alli" because it's supposed to be "allied" with a weight-loss program, including exercise and healthy eating, reports CBS News correspondent Dan Raviv.
The drug is intended for people 18 and older to use along with a reduced-calorie, low-fat diet and exercise.
Dr. Charles Ganley, FDA's director of nonprescription products, stressed that the drug is intended for use along with diet and exercise programs.
"Using this drug alone is unlikely to be beneficial," Ganley said at a telebriefing.
While some dietary supplements make weight-loss claims, Ganley said this is the first nonprescription drug approved by the agency for that purpose.
Ganley said in trials, for every five pounds people lost through diet and exercise, those using orlistat lost an additional two to three pounds.
When taken with meals, orlistat blocks the absorption of about one-quarter of any fat consumed. That fat — about 150 to 200 calories worth — is passed out of the body in stools, which can be loose as a result. About half of patients in trials experienced gastrointestinal side effects.
The agency recommended users take a multivitamin when using this drug.
The new drug would contain half the dose of Xenical prescription capsules. The price has not been set but is expected to run $1 to $2 a day, company officials said. The company estimated 5 million to 6 million Americans a year would buy the drug over the counter.
The Food and Drug Administration said the most common side effect of the product is a change in bowel habits including loose stool and some oily spotting. Eating a low-fat diet will reduce the likelihood of this side effect.
FDA said people who have had organ transplants should not take OTC orlistat because of possible drug interactions. In addition, anyone taking blood-thinning medicines or being treated for diabetes or thyroid disease should consult a physician before using orlistat, the agency said.
GSK Consumer Healthcare, which will market the pill, said it chose the name alli to indicate a partnership with consumers in their weight-loss efforts.
"We know that being overweight has many adverse consequences, including an increase in the risk of heart disease and type 2 diabetes," said Dr. Douglas Throckmorton, deputy director for the FDA's Center for Drug Evaluation and Research.
"OTC orlistat, along with diet and exercise, may aid overweight adults who seek to lose excess weight to improve their health," he said.
But Dr. Sidney M. Wolfe, director of Public Citizen's Health Research Group, called the approval "the height of recklessness." Wolfe said studies have associated the prescription version of the drug with precancerous lesions of the colon. He has also called for withdrawal of the prescription version.
The Food and Drug Administration said the fat-blocking weight-loss pill orlistat, which has been available by prescription, can be sold in a reduced-strength version over the counter.
The new version will be sold as "alli" by GlaxoSmithKline PLC. Xenical, the prescription version, is made by Roche Holding AG.
GlaxoSmithKline chose the name "alli" because it's supposed to be "allied" with a weight-loss program, including exercise and healthy eating, reports CBS News correspondent Dan Raviv.
The drug is intended for people 18 and older to use along with a reduced-calorie, low-fat diet and exercise.
Dr. Charles Ganley, FDA's director of nonprescription products, stressed that the drug is intended for use along with diet and exercise programs.
"Using this drug alone is unlikely to be beneficial," Ganley said at a telebriefing.
While some dietary supplements make weight-loss claims, Ganley said this is the first nonprescription drug approved by the agency for that purpose.
Ganley said in trials, for every five pounds people lost through diet and exercise, those using orlistat lost an additional two to three pounds.
When taken with meals, orlistat blocks the absorption of about one-quarter of any fat consumed. That fat — about 150 to 200 calories worth — is passed out of the body in stools, which can be loose as a result. About half of patients in trials experienced gastrointestinal side effects.
The agency recommended users take a multivitamin when using this drug.
The new drug would contain half the dose of Xenical prescription capsules. The price has not been set but is expected to run $1 to $2 a day, company officials said. The company estimated 5 million to 6 million Americans a year would buy the drug over the counter.
The Food and Drug Administration said the most common side effect of the product is a change in bowel habits including loose stool and some oily spotting. Eating a low-fat diet will reduce the likelihood of this side effect.
FDA said people who have had organ transplants should not take OTC orlistat because of possible drug interactions. In addition, anyone taking blood-thinning medicines or being treated for diabetes or thyroid disease should consult a physician before using orlistat, the agency said.
GSK Consumer Healthcare, which will market the pill, said it chose the name alli to indicate a partnership with consumers in their weight-loss efforts.
"We know that being overweight has many adverse consequences, including an increase in the risk of heart disease and type 2 diabetes," said Dr. Douglas Throckmorton, deputy director for the FDA's Center for Drug Evaluation and Research.
"OTC orlistat, along with diet and exercise, may aid overweight adults who seek to lose excess weight to improve their health," he said.
But Dr. Sidney M. Wolfe, director of Public Citizen's Health Research Group, called the approval "the height of recklessness." Wolfe said studies have associated the prescription version of the drug with precancerous lesions of the colon. He has also called for withdrawal of the prescription version.
-
Scott Conroy Scott Conroy is a National Political Reporter for RealClearPolitics and a contributor for CBS News.
Follow on Twitter »
Popular Now in Health
- America's sodium problem: Not from salty snacks?
- Caffeine inhalers - the next club drug?
- Chinese mom gives birth to 15-pound baby
- Norovirus outbreak hits Rider University in N.J
- Electric shocks to brain may boost memory: Study
- STD rates rise among elderly: Why?
- Skin cancer self-exam: What to look for (PHOTOS)
- Scottish twins, 102, are world's oldest: Guinness
- Measles patient at Super Bowl prompts health alert
- America's pets also have an obesity epidemic
- Drinking soda raises risk for asthma, COPD: Study
- Things You Didn't Know About Your Penis
- PICTURES: 15 Shocking Sexual Fetishes
- Dr. Liar? Study finds dishonest docs common
- Egg recall in 34 states over Listeria concerns
- McDonald's scraps "pink slime" from burgers
- Woman spotlights uterus didelphys on talk show
Latest CBS News Headlines
on Facebook
on CBS News
- What earnings reports reveal about entertainment
- Obama: Religious liberty will be protected; women will still be able to get contraception
- A look at tech companies with IPOs this year
- A look at recent tech-industry earnings
on Facebook
- Adele sings a cappella for Anderson Cooper
- Tenn. father charged with murdering couple who"unfriended" daughter on Facebook
- Josh Powell had "incestuous" images on his home computer, authorities say
on CBS News






